These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
262 related articles for article (PubMed ID: 19863050)
1. From serendipity to rational antituberculosis drug discovery of mefloquine-isoxazole carboxylic acid esters. Mao J; Yuan H; Wang Y; Wan B; Pieroni M; Huang Q; van Breemen RB; Kozikowski AP; Franzblau SG J Med Chem; 2009 Nov; 52(22):6966-78. PubMed ID: 19863050 [TBL] [Abstract][Full Text] [Related]
2. Synthesis and antituberculosis activity of novel mefloquine-isoxazole carboxylic esters as prodrugs. Mao J; Yuan H; Wang Y; Wan B; Pak D; He R; Franzblau SG Bioorg Med Chem Lett; 2010 Feb; 20(3):1263-8. PubMed ID: 20022500 [TBL] [Abstract][Full Text] [Related]
3. HTS, chemical hybridization, and drug design identify a chemically unique antituberculosis agent-coupling serendipity and rational approaches to drug discovery. Mao J; Wan B; Wang Y; Franzblau SG; Kozikowski AP ChemMedChem; 2007 Jun; 2(6):811-3. PubMed ID: 17455191 [No Abstract] [Full Text] [Related]
4. Rational design of 5-phenyl-3-isoxazolecarboxylic acid ethyl esters as growth inhibitors of Mycobacterium tuberculosis. a potent and selective series for further drug development. Lilienkampf A; Pieroni M; Wan B; Wang Y; Franzblau SG; Kozikowski AP J Med Chem; 2010 Jan; 53(2):678-88. PubMed ID: 20000577 [TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and pharmacological evaluation of mefloquine-based ligands as novel antituberculosis agents. Mao J; Wang Y; Wan B; Kozikowski AP; Franzblau SG ChemMedChem; 2007 Nov; 2(11):1624-30. PubMed ID: 17680579 [TBL] [Abstract][Full Text] [Related]
6. Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis. Lilienkampf A; Mao J; Wan B; Wang Y; Franzblau SG; Kozikowski AP J Med Chem; 2009 Apr; 52(7):2109-18. PubMed ID: 19271749 [TBL] [Abstract][Full Text] [Related]
7. Synthesis, biological evaluation, and structure-activity relationships for 5-[(E)-2-arylethenyl]-3-isoxazolecarboxylic acid alkyl ester derivatives as valuable antitubercular chemotypes. Pieroni M; Lilienkampf A; Wan B; Wang Y; Franzblau SG; Kozikowski AP J Med Chem; 2009 Oct; 52(20):6287-96. PubMed ID: 19757815 [TBL] [Abstract][Full Text] [Related]
8. Antitubercular activities of novel benzothiazolo naphthyridone carboxylic acid derivatives endowed with high activity toward multi-drug resistant tuberculosis. Dinakaran M; Senthilkumar P; Yogeeswari P; Sriram D Biomed Pharmacother; 2009 Jan; 63(1):11-8. PubMed ID: 18078735 [TBL] [Abstract][Full Text] [Related]
9. Discovery of new 1,3,5-triazine scaffolds with potent activity against Mycobacterium tuberculosis H37Rv. Sunduru N; Gupta L; Chaturvedi V; Dwivedi R; Sinha S; Chauhan PM Eur J Med Chem; 2010 Aug; 45(8):3335-45. PubMed ID: 20452706 [TBL] [Abstract][Full Text] [Related]
10. Identification, synthesis, and pharmacological evaluation of tetrahydroindazole based ligands as novel antituberculosis agents. Guo S; Song Y; Huang Q; Yuan H; Wan B; Wang Y; He R; Beconi MG; Franzblau SG; Kozikowski AP J Med Chem; 2010 Jan; 53(2):649-59. PubMed ID: 20000470 [TBL] [Abstract][Full Text] [Related]
11. Derivatives of 3-isoxazolecarboxylic acid esters: a potent and selective compound class against replicating and nonreplicating Mycobacterium tuberculosis. Lilienkampf A; Pieroni M; Franzblau SG; Bishai WR; Kozikowski AP Curr Top Med Chem; 2012; 12(7):729-34. PubMed ID: 22283815 [TBL] [Abstract][Full Text] [Related]
12. Searching for new cures for tuberculosis: design, synthesis, and biological evaluation of 2-methylbenzothiazoles. Huang Q; Mao J; Wan B; Wang Y; Brun R; Franzblau SG; Kozikowski AP J Med Chem; 2009 Nov; 52(21):6757-67. PubMed ID: 19817445 [TBL] [Abstract][Full Text] [Related]
14. Development of antitubercular compounds based on a 4-quinolylhydrazone scaffold. Further structure-activity relationship studies. Gemma S; Savini L; Altarelli M; Tripaldi P; Chiasserini L; Coccone SS; Kumar V; Camodeca C; Campiani G; Novellino E; Clarizio S; Delogu G; Butini S Bioorg Med Chem; 2009 Aug; 17(16):6063-72. PubMed ID: 19620006 [TBL] [Abstract][Full Text] [Related]
15. Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines. Protopopova M; Hanrahan C; Nikonenko B; Samala R; Chen P; Gearhart J; Einck L; Nacy CA J Antimicrob Chemother; 2005 Nov; 56(5):968-74. PubMed ID: 16172107 [TBL] [Abstract][Full Text] [Related]
17. Antimycobacterial activities of novel 1-(cyclopropyl/tert-butyl/4-fluorophenyl)-1,4-dihydro- 6-nitro-4-oxo-7-(substituted secondary amino)-1,8-naphthyridine-3-carboxylic acid. Sriram D; Senthilkumar P; Dinakaran M; Yogeeswari P; China A; Nagaraja V J Med Chem; 2007 Nov; 50(24):6232-9. PubMed ID: 17960928 [TBL] [Abstract][Full Text] [Related]
18. Synthesis and characterization of novel hydrazide-hydrazones and the study of their structure-antituberculosis activity. Bedia KK; Elçin O; Seda U; Fatma K; Nathaly S; Sevim R; Dimoglo A Eur J Med Chem; 2006 Nov; 41(11):1253-61. PubMed ID: 16919372 [TBL] [Abstract][Full Text] [Related]
19. Synthesis, in vitro and in vivo antimycobacterial activities of diclofenac acid hydrazones and amides. Sriram D; Yogeeswari P; Devakaram RV Bioorg Med Chem; 2006 May; 14(9):3113-8. PubMed ID: 16412646 [TBL] [Abstract][Full Text] [Related]
20. Discovery of novel antitubercular 2,10-dihydro-4aH-chromeno[3,2-c]pyridin-3-yl derivatives. Sriram D; Yogeeswari P; Dinakaran M; Banerjee D; Bhat P; Gadhwal S Eur J Med Chem; 2010 Jan; 45(1):120-3. PubMed ID: 19942326 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]